ZARZA We are Zarza, the prestigious firm behind major projects in information technology.

TMO EPM / Hemato H9J

Por: TMO EPM / Hemato H9J

Podcast de discussão de assuntos em Hematologia do Transplante de Medula Óssea da Escola Paulista de Medicina (UNIFESP) e da Hematologia do Hospital 9 de Julho - DASA

65 episodios disponibles

Últimos episódios do podcast TMO EPM / Hemato H9J

Mostrando página 2 de 4

45 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma 26/12/2024

44 - Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML 23/12/2024

43 - Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma 27/11/2024

42 - Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21) 23/11/2024

41 - An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease 01/11/2024

40 - Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission 27/09/2024

39 - Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors 25/09/2024

38 - Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma 19/09/2024

37 - Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults 24/08/2024

36 - Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma 16/08/2024

35 - A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia 05/08/2024

34 - Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission 27/07/2024

33 - Asciminib in Newly Diagnosed Chronic Myeloid Leukemia 14/07/2024

32 - The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial 12/07/2024

31 - Remission induction vs immediate allogeneic HSCT for patients with relapsed or poor responsive AML (ASAP): a randomised, open-label, phase 3, non-inferiority trial 05/07/2024

30 - Ibrutinib combined with immunochemotherapy with or without ASCT vs immunochemotherapy and ASCT in previously untreated patients with mantle cell lymphoma (TRIANGLE) 03/07/2024

29 - Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT 27/05/2024

28 - Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial 24/04/2024

27 - Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma 14/04/2024

26 - Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3 06/04/2024

« Primera ‹ Anterior 1 2 3 4 Siguiente › Última »